IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing.
Anna W LaVigneDanielle N MargalitBhupendra RawalMaria PuzanovDonald J AnninoLaura A GoguenDavid J SherJonathan D SchoenfeldNicole G ChauJochen H LorchGuilherme RabinowitsRobert I HaddadRoy B TishlerPublished in: Head & neck (2019)
In this single institution study, a 56 Gy IMRT-based mucosal dose demonstrated significant improvements in swallowing toxicity. Additional benefit was seen with larynx-sparing IMRT.